-
1
Gynecologic cancers, including cervical, endometrial, and ovarian cancers, pose significant health risks and have high mortality rates.
-
2
Immune checkpoint inhibitors (ICIs) have shown promise in treating advanced gynecologic cancers but often have low response rates as monotherapy.
-
3
Combination strategies involving ICIs with chemotherapy, radiotherapy, PARP inhibitors, and anti-angiogenic agents are being explored to enhance treatment efficacy.
-
4
Endometrial cancer shows the most robust evidence for ICI benefit, particularly in the MSI-H/dMMR molecular subtype.
-
5
Challenges in ICI therapy include drug resistance, adverse events, and the need for better biomarkers and clinical trial designs.
